Guizhou Bailing Group Pharmaceutical Co Ltd (SHE:002424) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Bailing Group Pharmaceutical Co Ltd (002424)
Guizhou Bailing Group Pharmaceutical Co Ltd (SHE:002424) has a market capitalization of $912.13 Million (CN¥6.23 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9338 globally and #2335 in its home market, demonstrating a -5.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Bailing Group Pharmaceutical Co Ltd's stock price CN¥4.46 by its total outstanding shares 1397598400 (1.40 Billion). Also see balance sheet size of Guizhou Bailing Group Pharmaceutical Co for a full breakdown of the balance sheet.
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Bailing Group Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $5.00 Billion to $912.13 Million (-13.79% CAGR). Also see Guizhou Bailing Group Pharmaceutical Co cash conversion from operations for how efficiently the company converts equity into cash flow.
Guizhou Bailing Group Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Bailing Group Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Guizhou Bailing Group Pharmaceutical Co stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.29x
Guizhou Bailing Group Pharmaceutical Co Ltd's market cap is 0.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.71 Billion | $2.21 Billion | $482.33 Million | 1.67x | 7.68x |
| 2017 | $3.03 Billion | $2.59 Billion | $526.14 Million | 1.17x | 5.76x |
| 2018 | $1.73 Billion | $3.14 Billion | $563.24 Million | 0.55x | 3.07x |
| 2019 | $1.74 Billion | $2.85 Billion | $282.75 Million | 0.61x | 6.14x |
| 2020 | $1.60 Billion | $3.09 Billion | $152.38 Million | 0.52x | 10.51x |
| 2021 | $1.55 Billion | $3.11 Billion | $118.48 Million | 0.50x | 13.12x |
| 2022 | $1.67 Billion | $3.54 Billion | $138.47 Million | 0.47x | 12.05x |
| 2023 | $1.66 Billion | $4.26 Billion | -$414.51 Million | 0.39x | N/A |
| 2024 | $787.37 Million | $3.83 Billion | $33.62 Million | 0.21x | 23.42x |
| 2025 | $889.63 Million | $3.05 Billion | -$104.37 Million | 0.29x | N/A |
Competitor Companies of 002424 by Market Capitalization
Companies near Guizhou Bailing Group Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Guizhou Bailing Group Pharmaceutical Co tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guizhou Bailing Group Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Guizhou Bailing Group Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Bailing Group Pharmaceutical Co Ltd's market cap moved from $5.00 Billion to $ 912.13 Million, with a yearly change of -13.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥912.13 Million | +2.53% |
| 2025 | CN¥889.63 Million | +12.99% |
| 2024 | CN¥787.37 Million | -52.53% |
| 2023 | CN¥1.66 Billion | -0.61% |
| 2022 | CN¥1.67 Billion | +7.37% |
| 2021 | CN¥1.55 Billion | -2.94% |
| 2020 | CN¥1.60 Billion | -7.77% |
| 2019 | CN¥1.74 Billion | +0.30% |
| 2018 | CN¥1.73 Billion | -42.83% |
| 2017 | CN¥3.03 Billion | -18.30% |
| 2016 | CN¥3.71 Billion | -25.82% |
| 2015 | CN¥5.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Guizhou Bailing Group Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $912.13 Million USD |
| MoneyControl | $912.13 Million USD |
| MarketWatch | $912.13 Million USD |
| marketcap.company | $912.13 Million USD |
| Reuters | $912.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more